Screener / SEC EDGAR /CIK 0000818479 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Dental Equipment & Supplies

DENTSPLY SIRONA Inc. XRAY

Compare with peers Embed
FY2025 at a glance

Sales down 3.0%, free cash flow down to $104.0M

XBRL, from each 10-K
RevenueStatements
$3.7B from $3.8B in FY2024
FY2016FY2025
Net incomeStatements
-$598.0M from -$910.0M in FY2024
FY2016FY2025
Free cash flowStatements
$104.0M from $281.0M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-3.00 from $-4.48 in FY2024
FY2016FY2025
Operating marginStatements
-11.5% from -23.2% in FY2024
FY2016FY2025
Total debtStatements
$2.4B from $2.2B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (38)
EPS (ttm)
-0.61
Sales (ttm)
3.6B
Net income (ttm)
-121.0M
Sales growth
-3.0%
EPS growth
-
Sales Q/Q
-7.5%
Free cash flow
103.0M
Gross margin
50.5%
Oper. margin
-1.5%
Net margin
-3.4%
FCF margin
2.9%
R&D / sales
4.1%
Dividend
0.64
Debt/Eq
1.62
Curr. ratio
1.63
Cash
195.0M
Op. cash flow (ttm)
272.0M
EBITDA
-70.0M
EBITDA margin
-1.9%
Net debt
2.0B
Quick ratio
1.10
Interest cover
-4.80
FCF after stock pay
71.0M
Debt / FCF (years)
21.15
Goodwill / assets
21.1%
Oper. margin low 5y
-23.9%
Stock pay / sales
0.9%
Shares out.
198.2M
Shares Y/Y
-1.9%
Book / share
6.84
Cash / share
0.98
Sales / share
18.04
Asset turnover
0.69
Inventory turns
2.87
Sales 3Y CAGR
-2.1%
Sales 5Y CAGR
+2.0%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.7B -0.2% a year Net income -598.0M
FY2016 revenue 3.7B · SalesRevenueNet, 0000818479-18-000014 FY2016 net income 429.9M · NetIncomeLoss, 0000818479-19-000010 3.7B FY2016 FY2017 revenue 4.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-20-000006 FY2017 net income -1.6B · NetIncomeLoss, 0000818479-20-000006 4.0B FY2017 FY2018 revenue 4.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-21-000007 FY2018 net income -1.0B · NetIncomeLoss, 0000818479-21-000007 4.0B FY2018 FY2019 revenue 4.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-22-040131 FY2019 net income 256.0M · NetIncomeLoss, 0001140361-22-040131 4.0B FY2019 FY2020 revenue 3.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-23-000062 FY2020 net income -73.0M · NetIncomeLoss, 0000818479-23-000062 3.3B FY2020 FY2021 revenue 4.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-24-000021 FY2021 net income 411.0M · NetIncomeLoss, 0000818479-24-000021 4.2B FY2021 FY2022 revenue 3.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-25-000035 FY2022 net income -950.0M · NetIncomeLoss, 0000818479-25-000035 3.9B FY2022 FY2023 revenue 4.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-26-000075 FY2023 net income -132.0M · NetIncomeLoss, 0000818479-26-000075 4.0B FY2023 FY2024 revenue 3.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-26-000075 FY2024 net income -910.0M · NetIncomeLoss, 0000818479-26-000075 3.8B FY2024 FY2025 revenue 3.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000818479-26-000075 FY2025 net income -598.0M · NetIncomeLoss, 0000818479-26-000075 3.7B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
50 100 Revenue: $3.7B in FY2016, $3.7B in FY2025 REVENUE $3.7B · 1.0x Free cash flow: $438.4M in FY2016, $104.0M in FY2025 FREE CASH FLOW $104.0M · 0.2x FY2016 = 100FY2021FY2025
Revenue 1.0x $3.7B to $3.7B
Free cash flow 0.2x $438.4M to $104.0M

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -8.5% a year FY2015 $16.41 to FY2025 $6.72, 10 years
Free cash flow per share -16.0% a year FY2015 $2.99 to FY2025 $0.52, 10 years
100 200 Book value / share: $16.41 in FY2015, $6.72 in FY2025 BOOK VALUE / SHARE $6.72 · 0.4x FCF / share: $2.99 in FY2015, $0.52 in FY2025 FCF / SHARE $0.52 · 0.2x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$3.00$6.72$0.52
Dec 31, 2024 -$4.48$9.56$1.38
Dec 31, 2023 -$0.62$15.53$1.08
Dec 31, 2022 -$4.41$17.68$1.71
Dec 31, 2021 $1.87$22.69$2.34
Dec 31, 2020 -$0.33$22.50$2.56
Dec 31, 2019 $1.14$22.70$2.30
Dec 31, 2018 -$4.51$22.83$1.41
Dec 31, 2017 -$6.76$28.84$1.99
Dec 31, 2016 $1.94$36.62$1.98
Dec 31, 2015 $1.76$16.41$2.99

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $2.0B
  • − All liabilities $4.1B
  • = Net current asset value -$2.1B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.3B
  • − Goodwill $1.1B
  • − Other intangible assets $974.0M
  • = Tangible book value -$783.0M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

XRAY against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
-3.0%145th of 155 · median +10.5%
Net margin
-4.1%15.3%
-3.4%115th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-8.9%112th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
2.9%106th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.6292nd of 108 · median 0.69
XRAY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
XRAY DENTSPLY SIRONA Inc.$3.6B -3.0%50.5%-3.4%-8.9%2.9%1.62
NBIX Neurocrine Biosciences Inc$3.7B +21.4%-19.0%18.1%28.1%-
BMRN Biomarin Pharmaceutical Inc$3.7B +12.9%76.0%-0.5%-0.3%15.3%0.67
VEEV Veeva Systems$3.5B +16.3%75.0%29.3%13.7%--
ACHC Acadia Healthcare Company, Inc.$3.4B +5.0%--33.1%-55.8%-0.7%1.16
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $4.2B of sales to $411.0M of profit FY2021

  • Essential Dental Solutions $1.5B
  • Connected Technology Solutions $1.3B
  • Orthodontic and Implant Solutions $1.1B
  • Wellspect Healthcare $303.0M
Revenue to Gross profit: $2.3BRevenue to Cost of revenue: $1.9BGross profit to Operating profit: $608.0MGross profit to Operating expenses: $1.7BOperating profit to Net profit: $411.0MOperating profit to Tax & other: $197.0MOperating expenses to R&D: $171.0MOperating expenses to SG&A: $1.6B Revenue: $4.2B REVENUE $4.2B +27% Y/Y Gross profit: $2.3B · 55% margin GROSS PROFIT $2.3B 55% margin · +42% Y/Y Cost of revenue: $1.9B · 45% of revenue COST OF REVENUE $1.9B 45% of revenue Operating profit: $608.0M · 14% margin OPERATING PROFIT $608.0M 14% margin Operating expenses: $1.7B · 41% of revenue OPERATING EXPENSES $1.7B 41% of revenue Net profit: $411.0M · 10% margin NET PROFIT $411.0M 10% margin Tax & other: $197.0M · 5% of revenue TAX & OTHER $197.0M 5% of revenue R&D: $171.0M · 4% of revenue R&D $171.0M 4% of revenue SG&A: $1.6B · 37% of revenue SG&A $1.6B 37% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -44.7% FY2020: -1.5% net income ÷ equity
Net margin -16.2% FY2020: -2.2% profit per $ of sales: -598.0M ÷ 3.7B
Asset turnover 0.68× FY2020: 0.36× sales per $ of assets: 3.7B ÷ 5.4B
Leverage 4.05× FY2020: 1.90× assets per $ of equity: 5.4B ÷ 1.3B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -3.4% vs 6.8%
  • Gross margin up over 5 years
    49.6% → 50.0%
  • Return on equity below 15%
    -8.9%
  • A profit in 3 of 10 years
Net margin, FY2016 to FY2025: 11.5% to -16.2%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -4.8× interest expense
  • Debt larger than equity
    Debt / equity 1.62 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.63
  • Net debt over 3 years of free cash flow
    $2.0B net debt, 19.5 years
Debt / equity at each year end, FY2016 to FY2025: 0.19 to 1.76

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $104.0M last year
  • Share count down over 5 years
    −9.0%
  • Dividend per share up over 5 years
    $0.40 → $0.64
Free cash flow, FY2016 to FY2025: 438.4M to 104.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.3B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $99.0M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · -18.9% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

XRAY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.7B
FY2016: 3.7BFY2017: 4.0BFY2018: 4.0BFY2019: 4.0BFY2020: 3.3BFY2021: 4.2BFY2022: 3.9BFY2023: 4.0BFY2024: 3.8BFY2025: 3.7B FY2017FY2019FY2021FY2023FY2025
Net income-598.0M
FY2016: 429.9MFY2017: -1.6BFY2018: -1.0BFY2019: 256.0MFY2020: -73.0MFY2021: 411.0MFY2022: -950.0MFY2023: -132.0MFY2024: -910.0MFY2025: -598.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow104.0M
FY2016: 438.4MFY2017: 457.6MFY2018: 317.0MFY2019: 516.0MFY2020: 562.0MFY2021: 515.0MFY2022: 368.0MFY2023: 228.0MFY2024: 281.0MFY2025: 104.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay71.0M
FY2016: 397.1MFY2017: 409.6MFY2018: 296.0MFY2019: 450.0MFY2020: 515.0MFY2021: 467.0MFY2022: 309.0MFY2023: 182.0MFY2024: 242.0MFY2025: 71.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-3.00
FY2016: 1.94FY2017: -6.76FY2018: -4.51FY2019: 1.14FY2020: -0.33FY2021: 1.87FY2022: -4.41FY2023: -0.62FY2024: -4.48FY2025: -3.00 FY2017FY2019FY2021FY2023FY2025
Dividend per share0.64
FY2016: 0.31FY2017: 0.35FY2018: 0.35FY2019: 0.38FY2020: 0.40FY2021: 0.43FY2022: 0.50FY2023: 0.56FY2024: 0.64FY2025: 0.64 FY2017FY2019FY2021FY2023FY2025
Diluted shares199.4M
FY2016: 221.6MFY2017: 229.4MFY2018: 224.3MFY2019: 224.4MFY2020: 219.2MFY2021: 220.2MFY2022: 215.5MFY2023: 212.0MFY2024: 203.2MFY2025: 199.4M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Essential Dental Solutions 1.5B39.9% +1.0%
Connected Technology Solutions 1.0B28.2% -2.4%
Orthodontic and Implant Solutions 850.0M23.1% -12.6%
Wellspect Healthcare 325.0M8.8% +6.9%

10-K 0000818479-26-000075, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
Other Foreign 2.1B56.4% +2.0%
Europe 1.6B42.8% +3.8%
United States 1.2B32.1% -12.3%
Rest of World 922.0M25.1% -0.5%
Germany 422.0M11.5% +2.9%

10-K 0000818479-26-000075, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Essential Dental Solutions1.5B1.4B1.5B1.5B1.5B
Connected Technology Solutions1.3B1.2B1.2B1.1B1.0B
Orthodontic and Implant Solutions1.1B1.0B1.0B973.0M850.0M
Wellspect Healthcare303.0M270.0M288.0M304.0M325.0M
Sum of segments4.2B3.9B4.0B3.8B3.7B

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Essential Dental Solutions511.0M467.0M478.0M479.0M514.0M
Orthodontic and Implant Solutions217.0M193.0M156.0M80.0M108.0M
Wellspect Healthcare87.0M73.0M87.0M98.0M102.0M
Connected Technology Solutions267.0M161.0M101.0M70.0M52.0M

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue3.7B4.0B4.0B4.0B3.3B4.2B3.9B4.0B3.8B3.7B
Cost of revenue1.7B1.8B1.9B1.9B1.7B1.9B1.8B1.9B1.8B1.8B
Gross profit2.0B2.2B2.1B2.2B1.7B2.3B2.1B2.1B2.0B1.8B
R&D128.5M151.7M161.0M143.0M123.0M171.0M174.0M184.0M165.0M150.0M
SG&A1.5B1.7B1.7B1.6B1.3B1.6B1.6B1.6B1.6B1.4B
Operating income454.7M-1.6B-958.0M353.0M-3.0M608.0M-937.0M-85.0M-879.0M-422.0M
Interest expense35.9M38.3M37.0M30.0M48.0M61.0M65.0M81.0M69.0M88.0M
Pretax income440.9M-1.6B-958.0M338.0M-50.0M545.0M-1.1B-175.0M-936.0M-486.0M
Income tax9.5M-53.2M53.0M82.0M23.0M134.0M-105.0M-43.0M-26.0M112.0M
Net income429.9M-1.6B-1.0B256.0M-73.0M411.0M-950.0M-132.0M-910.0M-598.0M
EPS (diluted)1.94-6.76-4.511.14-0.331.87-4.41-0.62-4.48-3.00
Diluted shares221.6M229.4M224.3M224.4M219.2M220.2M215.5M212.0M203.2M199.4M
Depreciation & amortization271.7M316.4M331.0M323.0M334.0M347.0M328.0M343.0M349.0M352.0M
EBITDA726.4M-1.2B-627.0M676.0M331.0M955.0M-609.0M258.0M-530.0M-70.0M
Gross margin53.4%54.8%51.9%53.8%49.6%55.5%54.2%52.6%51.6%50.0%
Operating margin12.1%-39.1%-24.0%8.8%-0.1%14.4%-23.9%-2.1%-23.2%-11.5%
Net margin11.5%-38.8%-25.4%6.4%-2.2%9.7%-24.2%-3.3%-24.0%-16.2%
Revenue growth+40.0%+6.6%-0.2%+0.9%-17.0%+26.7%-7.3%+1.1%-4.3%-3.0%
EPS growth+10.2%to a loss--to a loss-to a loss---

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)41.3M48.0M21.0M66.0M47.0M48.0M59.0M46.0M39.0M33.0M
Stock-based pay / revenue1.1%1.2%0.5%1.6%1.4%1.1%1.5%1.2%1.0%0.9%
Operating lease cost---55.0M57.0M67.0M68.0M67.0M67.0M65.0M
Operating lease cash paid---56.0M56.0M65.0M66.0M68.0M67.0M62.0M
Finance lease principal paid---200K------
Right-of-use assets---159.0M176.0M198.0M200.0M178.0M136.0M139.0M
Operating lease liabilities---163.2M178.0M199.0M203.0M181.0M137.0M140.0M
Finance lease liabilities---1.5M1.0M2.0M2.0M1.0M--

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XRAY/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.